The alignment with the FDA and EMA is a significant regulatory milestone for 89bio and its drug Pegozafermin. This positive development is likely to be viewed favorably by investors, as it suggests a clear regulatory path forward and may increase the likelihood of the drug reaching the market. The initiation of the Phase 3 program is a critical step in drug development, and successful trials could lead to eventual approval and commercialization, which would have a substantial impact on the company's revenues and growth prospects.